Alfuzosin HCl is a pharmaceutical drug of the alpha-1 blocker class. As an antagonist of the alpha-1 adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. It is thus used to treat benign prostatic hyperplasia (BPH). Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradename Xat or Xatral, and in Egypt under name of Prostetrol. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.
Synthetic Routes
Alfuzosin HCl-Route 01
Synthetic Reference
Manoury, Philippe M.; Binet, Jean L.; Dumas, Andre P.; Lefevre-Borg, Francoise; Cavero, Icilio. Synthesis and antihypertensive activity of a series of 4-amino-6,7-dimethoxyquinazoline derivatives. Journal of Medicinal Chemistry. Volume 29. Issue 1. Pages 19-25. 1986.
Wang, Haiyan; Luo, Wengong; Zhang, Lulu. Improved process for preparing Alfuzosin hydrochloride. Assignee Liaoning Keji Pharmaceutical Co., Ltd., 2018.
Alfuzosin HCl-Route 07
Synthetic Reference
Keshav, Deo; Sanjay, Desai; Mohansihn, Rathod Dhiraj; Chandrakant, Parikh Chirag; Kantibhai, Patel Ripalkumar; Suresh, Mistry Chirayu. A process for the preparation of alfuzosin hydrochloride. Assignee Alembic Limited, India. 2010.
Alfuzosin HCl-Route 08
Synthetic Reference
Zhang, Peng. Process for preparing Alfuzosin hydrochloride. Assignee Liaoning Keji Pharmaceutical Co., Ltd. 2017.
Alfuzosin HCl-Route 09
Synthetic Reference
Li, Jiarong; Shi, Daxin; Chen, Xian; Zhang, Qi; Li, Ying. Method for preparation of Alfuzosin hydrochloride. Assignee Beijing Institute of Technology. 2010.